Roivant Sciences Management
Management criteria checks 4/4
Roivant Sciences' CEO is Matt Gline, appointed in Jan 2021, has a tenure of 3.75 years. total yearly compensation is $738.19K, comprised of 98.2% salary and 1.8% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth €97.29K. The average tenure of the management team and the board of directors is 3.8 years and 3.1 years respectively.
Key information
Matt Gline
Chief executive officer
US$738.2k
Total compensation
| CEO salary percentage | 98.2% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.001% |
| Management average tenure | 3.8yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$5b |
| Mar 31 2024 | US$738k | US$725k | US$4b |
| Dec 31 2023 | n/a | n/a | US$4b |
| Sep 30 2023 | n/a | n/a | -US$1b |
| Jun 30 2023 | n/a | n/a | -US$1b |
| Mar 31 2023 | US$49m | US$725k | -US$1b |
| Dec 31 2022 | n/a | n/a | -US$1b |
| Sep 30 2022 | n/a | n/a | -US$1b |
| Jun 30 2022 | n/a | n/a | -US$1b |
| Mar 31 2022 | US$30m | US$725k | -US$845m |
| Dec 31 2021 | n/a | n/a | -US$1b |
| Sep 30 2021 | n/a | n/a | -US$1b |
| Jun 30 2021 | n/a | n/a | -US$888m |
| Mar 31 2021 | US$8m | US$350k | -US$809m |
Compensation vs Market: Matt's total compensation ($USD738.19K) is below average for companies of similar size in the German market ($USD3.46M).
Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.
CEO
Matt Gline (40 yo)
3.8yrs
Tenure
US$738,189
Compensation
Mr. Matthew Gline, also known as Matt, is Chief Executive Officer of Roivant Sciences Ltd. since January 26, 2021 and its Director since September 30, 2021. He has been Chief Executive Officer of Roivant S...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.8yrs | US$738.19k | 0.0012% € 97.3k | |
| President | 3.8yrs | US$574.56k | 0.49% € 40.0m | |
| Chief Financial Officer | 3.1yrs | US$5.15m | 0.019% € 1.6m | |
| Chief Accounting Officer | 6.2yrs | US$4.33m | 0.015% € 1.2m | |
| President & COO | 5.9yrs | US$48.49m | 0.036% € 2.9m | |
| Chief Information Officer | no data | no data | no data | |
| General Counsel | no data | no data | no data | |
| Head of People | 2.8yrs | no data | no data | |
| Executive Vice President of Roivant Health | no data | no data | no data | |
| Chief Operating Officer of Roivant Platforms | no data | no data | no data | |
| Chief Development Officer | 2.4yrs | no data | no data | |
| Chief Scientific Officer of Dermavant | no data | no data | no data |
3.8yrs
Average Tenure
44yo
Average Age
Experienced Management: 87S's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.1yrs | US$738.19k | 0.0012% € 97.3k | |
| President | less than a year | US$574.56k | 0.49% € 40.0m | |
| Independent Director | 1.6yrs | US$941.68k | 0.0018% € 141.9k | |
| Independent Director | 10.8yrs | US$442.59k | 0.17% € 13.8m | |
| Independent Director | 3.1yrs | US$459.24k | 0.010% € 833.5k | |
| Independent Director | 4.8yrs | US$449.24k | 0.87% € 70.5m | |
| Independent Director | 2.3yrs | US$444.24k | 0.0027% € 219.7k | |
| Independent Chairman | 10.8yrs | US$488.49k | 0.011% € 867.5k |
3.1yrs
Average Tenure
50yo
Average Age
Experienced Board: 87S's board of directors are considered experienced (3.1 years average tenure).